Molybdenum-99 (or Mo-99), is the most-used diagnostic medical isotope in the world, powering 40 million patient scans each year. Nearly half of those scans, critical for detecting life-threatening conditionslike heart disease and cancer, are performed in North America. At SHINE, wehave developed a revolutionary way to produce Mo-99 without using nuclear reactors.
Molybdenum-99 is the parent isotope of technetium-99m (Tc-99m), a short-lived, gamma-emitting isotope used in about 85% of all nuclear medicine diagnostic scans. The vast majority of the world’s supply comes from several aging nuclear reactors, none of which are in North America. Mo-99 has a 66-hour half-life, so about one-third of the product is lost during cross-continental transportation.
We plan to produce molybdenum-99 in the United States and Europe to bolster the supply chain and help solve chronic shortages of this critical medicine. Our proprietary fusion-driven medical isotope production process will not require a nuclear reactor and uses a recyclable liquid low-enriched-uranium target solution. We believe this will provide a safer, greener, more commercially viable method of supplying Mo-99 to the world.
Our production facility, The Chrysalis, has a goal of creating the largest dedicated medical isotope production capacity in the world. At full capacity, we’re planning to produce nearly half of the global demand for molybdenum-99. And our Mo-99 has been designed from the ground up to be compatible with the existing medical isotope supply chain for ease of customer use. A second facility planned in Veendam, the Netherlands, is expected to have a similar capacity.
We stand apart from other fusion companies because we have commercialized fusion today and we are scaling our technology. During each of our four phases, we’re perfecting core competencies needed for commercially viable fusion, producing useful products, building shareholder value, and reinvesting in future growth.
Join us and be part of the solution.
